2-(1-Benzofuran-4-yl)-N-methyl-N-[(5R,7R,8R)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-(1-Benzofuran-4-yl)-N-methyl-N-[(5R,7R,8R)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
• 化学式: C₂₄H₃₂N₂O₃
• 分子量: 396.5
• InChiKey: JMBYBVLCYODBJQ-LGVFNWMJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• REMEDIES FOR SEPSIS
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1402899A1

  公开（公告）日：2004-03-31

  A therapeutic agent for sepsis and various symptoms accompanying sepsis (such as septic shock, disseminated intravascular coagulation syndrome, adult respiratory distress syndrome and multiple organ dysfunction) is disclosed. The therapeutic agent for sepsis according to the present invention comprises as an effective ingredient an opioid κ receptor agonist compound such as (-)-17-(cyclopropylmethyl)-3,14β-dihydroxy-4,5α-epoxy-6β[N-methyl-trans-3-(3-furyl)acrylamide] oxide derivative. The opioid κ receptor agonist compound may be administered as it is or in the form of a pharmaceutical composition prepared by mixing the compound with a known pharmaceutically acceptable acid, carrier or vehicle orally or parenterally.

  本发明公开了一种治疗败血症和败血症伴随的各种症状（如脓毒性休克、弥散性血管内凝血综合征、成人呼吸窘迫综合征和多器官功能障碍）的药物。根据本发明的败血症治疗剂包括作为有效成分的阿片类κ受体激动剂化合物，如(-)-17-(环丙基甲基)-3,14β-二羟基-4,5α-环氧-6β[N-甲基-反式-3-(3-呋喃基)丙烯酰胺]氧化物衍生物。阿片κ受体激动剂化合物可以原样给药，也可以通过将该化合物与已知的药学上可接受的酸、载体或载体混合制备的药物组合物的形式口服或肠外给药。
• Remedies for sepsis
  申请人：——

  公开号：US20040147536A1

  公开（公告）日：2004-07-29

  A therapeutic agent for sepsis and various symptoms accompanying sepsis (such as septic shock, disseminated intravascular coagulation syndrome, adult respiratory distress syndrome and multiple organ dysfunction) is disclosed. The therapeutic agent for sepsis according to the present invention comprises as an effective ingredient an opioid &kgr; receptor agonist compound such as (−)-17-(cyclopropylmethyl)-3,14&bgr;-dihydroxy-4,5&agr;-epoxy-6&bgr;[N-methyl-trans-3-(3-furyl)acrylamide] oxide derivative. The opioid &kgr; receptor agonist compound may be administered as it is or in the form of a pharmaceutical composition prepared by mixing the compound with a known pharmaceutically acceptable acid, carrier or vehicle orally or parenterally.

  本发明公开了一种治疗败血症和败血症伴随的各种症状（如脓毒性休克、弥散性血管内凝血综合征、成人呼吸窘迫综合征和多器官功能障碍）的药物。根据本发明的败血症治疗剂包括作为有效成分的阿片受体激动剂化合物，如(-)-17-(环丙基甲基)-3,14&bgr;-二羟基-4,5&agr;-环氧-6&bgr;[N-甲基-反式-3-(3-呋喃基)丙烯酰胺]氧化物衍生物。阿片类&kgr;受体激动剂化合物可以原样给药，也可以通过将该化合物与已知的药学上可接受的酸、载体或载体混合制备的药物组合物的形式口服或肠外给药。
• 7-[(Substituted)amino]-8-[(substituted)carbonyl)-methylamino]-1-oxaspiro[4.5]decanes as analgesic agents
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0207773B1

  公开（公告）日：1990-01-03
• KAPPA AGONIST ANTI-PRURITIC PHARMACEUTICAL FORMULATIONS AND METHOD OF TREATING PRURITUS THEREWITH
  申请人：Adolor Corporation

  公开号：EP0996434A1

  公开（公告）日：2000-05-03
• EP0996434A4
  申请人：——

  公开号：EP0996434A4

  公开（公告）日：2001-10-10